CF
PRTK

Centaurus Financial’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Centaurus Financial’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$1K – 2180
2018
Q2 		$1K Buy
+100
New +$1.13K ﹤0.01% 2172

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Centaurus Financial's PRTK Position: Q3 2018 in Review

Centaurus Financial sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2018, closing a stake of 100 shares — an estimated $1K sold.

Centaurus Financial first reported a position in PRTK in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2018.

  • Centaurus Financial reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 100 Paratek Pharmaceuticals, Inc. shares in Q3 2018, an estimated $1K.
  • Centaurus Financial first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Paratek Pharmaceuticals, Inc. position peaked at $1K in Q2 2018.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.